Keio University Hospital has conducted clinical research for sub-acute spiral cord injury using neural progenitor cells derived from allogeneic iPS cells.

Under the Research Center Network for Realization of Regenerative Medicine, an industry-government-academia collaboration project, Sumitomo Pharma is working with Keio University and Osaka National Hospital as a contributing organization in the project on “regenerative medicine for spinal cord injury and stroke using iPS cell-derived neural progenitor cells.” We are responsible for research for practical use and verification of quality evaluation, and we aim to create treatment for chronic spinal cord injury using allogeneic iPS cell-derived neural progenitor cells.